Inside PIC/S: Top GMP Deficiencies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Top GMP Deficiencies
Comparison of the top GMP deficiencies cited by the PIC/S Participating Authorities.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 135-137

Results

Thirty-three out of 39 PIC/S Participating Authorities responded (85%). Seven out of 9 applicants to PIC/S responded (78%). The top most frequently cited categories of GMP deficiencies were:

  • Documentation—manufacturing (24)
  • Design and maintenance of premises (22)
  • Documentation—quality systems (elements / procedures) (20)
  • Personnel issues—training (19)
  • Design and maintenance of equipment (18)
  • Cleaning validation (14)
  • Process validation (14)
  • Product quality review (14)
  • Supplier and contractor audit (13)
  • Calibration of measuring and test equipment(12)
  • Equipment validation (11).

The total number of deficiencies per group of top 10 most frequently cited deficiencies were:

  • Production (99, or 24%)
  • Quality system (82, or 20%)
  • Quality control (59, or 14%)
  • Premises and equipment (58, or 14%)
  • Validation (52, or 12%)
  • Personnel issues (34, or 8%)
  • Materials management (29, or 7%)
  • Regulatory issues (5, or 1%)


Figure 1: Most severe cited GMP deficiencies.
The top most severe GMP deficiencies were (see Figure 1):
  • Design and maintenance of premises (15)
  • Contamination, potential for (chemical, physical, microbial) (12)
  • Design and maintenance of equipment (11)
  • Sterility assurance (9)
  • Batch-release procedures (9)
  • Process validation (9)
  • Cleaning validation (8)
  • Investigation of anomalies (7)
  • Documentation—quality systems (elements/procedures) (7)
  • Regulatory issues—noncompliance with marketing authorization (5)
  • Documentation—manufacturing (5).


Figure 2: Top most severe deficiencies by group.
The total number of deficiencies per group of the top most severe deficiencies were (see Figure 2):
  • Production (44, or 27%)
  • Quality system (32, or 20%)
  • Premises and equipment (28, or 17%)
  • Validation (22, or 14%)
  • Quality control (14, or 9%)
  • Regulatory issues (9, or 6%)
  • Materials management (8, or 5%)
  • Personnel issues (5 or 3%).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here